Ali S, Shakil O, Chen TH, Warraich HJ, Matyal R.
An incidental finding during emergent vascular surgery: how far to go?. J Cardiothorac Vasc Anesth. 2012;26 :354-5.
Warraich HJ, Chaudary B, Maslow A, Panzica PJ, Pugsley J, Mahmood F.
Mitral annular nonplanarity: correlation between annular height/commissural width ratio and the nonplanarity angle. J Cardiothorac Vasc Anesth. 2012;26 :186-90.
AbstractOBJECTIVE: To compare two methods of mitral annular nonplanarity: the mathematically calculated annular height-to-commissural width ratio (AHCWR) and the echocardiographically derived nonplanarity angle. DESIGN: Prospective. SETTING: Tertiary care university hospital. INTERVENTIONS: Three-dimensional transesophageal echocardiography. PARTICIPANTS: Patients undergoing mitral valve surgery. MEASUREMENTS AND MAIN RESULTS: Using 3-dimensional transesophageal echocardiography, volumetric datasets were acquired from 22 patients undergoing mitral valve surgery. The intraoperative nonplanarity angle was calculated with Mitral Valve Assessment software (Tomtec GmbH, Munich, Germany). Furthermore, the datasets acquired during 3-dimensional transesophageal echocardiography were exported to Matlab software (MathWorks, Natick, MA), which was used to calculate the AHCWR. The nonplanarity angle was seen to correlate favorably with the AHCWR (r = 0.70). CONCLUSIONS: A favorable correlation was found between the nonplanarity angle and the AHCWR. This suggests that the nonplanarity angle can be used to assess mitral annular nonplanarity in a clinically feasible fashion.
Khosa F, Warraich H, Khan A, Mahmood F, Markson L, Clouse ME, Manning WJ.
Prevalence of non-cardiac pathology on clinical transthoracic echocardiography. J Am Soc Echocardiogr. 2012;25 :553-7.
AbstractBACKGROUND: Non-cardiac findings (NCFs) are seen in more than a third of cardiac computed tomographic and cardiac magnetic resonance imaging studies. The prevalence and importance of NCFs in transthoracic echocardiographic (TTE) imaging is unknown. The aim of this study was to determine the prevalence of NCFs on TTE imaging. METHODS: The subcostal images of all comprehensive adult TTE studies performed at one institution in December 2008 were retrospectively reviewed for NCFs by a radiologist with fellowship training in cardiovascular and abdominal radiology and blinded to the TTE report findings and clinical histories. Additional TTE image orientations were assessed in a subset of 300 studies. NCFs were categorized as benign (e.g., simple hepatic cyst), indeterminate (e.g., ascites), or worrisome (e.g., liver metastases). If an indeterminate or worrisome NCF was identified, the patient's electronic medical record was reviewed to determine if the NCF was previously known. RESULTS: Of 1,008 TTE studies (443 inpatient, 565 outpatient) in 922 patients, 77 NCFs were identified in 69 patients (7.5%). These included 20 benign (26%), 52 indeterminate (67%), and five worrisome (7%) NCFs. Intermediate and worrisome NCFs were more common in inpatient TTE studies (9% vs 3% outpatient, P = .002). The additional views demonstrated 2% more NCFs. Record review demonstrated that 60% of worrisome and 67% of indeterminate NCFs were previously known. No unknown NCF ultimately led to a change in patient management. CONCLUSIONS: Clinical TTE studies demonstrate NCFs in 7.5% of all patients, with an increased prevalence on inpatient studies. Although 75% of NCFs were potentially management changing, the majority of these were previously known and very unlikely to lead to management changes. Further study is needed to validate these findings in other populations and to assess their clinical impact.
Burke DA, Warraich HJ, Pinto DS.
Which antithrombin for whom? Identifying the patient population that benefits most from novel antithrombin agents. Curr Cardiol Rep. 2012;14 :493-501.
AbstractAnticoagulation has proven to be a key component in the management of acute coronary syndromes (ACS). Pharmacological agents with various modes of action are utilized to reduce thrombus development by impairing thrombin formation, platelet activation, and platelet aggregation. The optimal management of these patients is to achieve maximal anti-ischemic benefit while avoiding bleeding complications. Synthetic "novel" agents have been developed to specifically target factor Xa or thrombin to achieve this goal. A growing amount of data show that these agents provide a net clinical benefit in the setting of stable ischemic heart disease, unstable angina, non-ST-elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI).